?> Oxford BioDynamics Plc A year of operational, scientific and commercial progress - DirectorsTalk

Be sure to check our sister interview main ratings news website

Oxford BioDynamics Plc A year of operational, scientific and commercial progress

Commenting on the results, Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

“In 2018 we have continued to build on the strong foundations established in 2017 following our successful IPO. Investment in our commercial infrastructure has allowed us to further our customer and geographical reach, with our EpiSwitch™ technology increasingly becoming the leading industry standard for identifying epigenetic biomarkers. We have signed multiple commercial development partnerships, in Europe, the US and China in new and challenging clinical indications. Our EpiSwitch™ platform is fast becoming internationally recognised as an effective and novel platform to improve therapeutic options. We were delighted to sign a strategic partnership with GL earlier this year, not only strengthening our cash position but also further establishing our position in the rapidly growing Chinese market. We look forward to reporting progress on the multiple projects currently underway.”

Oxford BioDynamics Plc (LON: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announced its audited results for the year ended 30 September 2018.

Corporate, operational and recent highlights

Six revenue-generating research and development projects for commercial customers in diverse fields including immuno-oncology, fibrosis and thyroid cancer.

Successful completion of Innovate UK grant-funded ALS project, followed by validation in peer-reviewed publication and expressions of commercial interest.

Announcement of strategic partnership in China with GL Capital Group (“GL”), a leading Chinese Healthcare Investment Group, with GL investing £9.75m and becoming a holder of 5% of the Company.

Significant progress in applying the EpiSwitch™ platform to areas of human and equine fitness, and announcement of a collaboration in the area of sports-related concussion.

Grant of core patents covering the EpiSwitch™ platform technology in the US, Canada and India. Two new patents filed along with extensive exemplification on previously filed patents.

Financial highlights

Revenue of £1.2m (FY17: £1.2m).

Operating loss of £2.6m (FY17: £4.0m).

Cash of £18.3m as at 30 September 2018 (FY17: £10.8m).

Post-period end

Announcement of fifth immuno-oncology (“IO”) collaboration, with a well-known US biopharmaceutical company.

Announcement of collaboration with Casa Sollievo della Sofferenza, a key national biomedical and healthcare institution in Italy, to develop a panel of epigenetic biomarkers for the diagnosis of Autistic Spectrum Disorder.

Exercise of option over 30% shareholding in commercial partner, Holos Life Sciences Pte Ltd (“Holos”).

Signing of two exclusive licence agreements with Holos, in the fields of human and equine performance and wellness.

Filing of one further patent, covering the use of the EpiSwitch™ platform in detecting disseminating biomarkers in the context of strength and endurance training for fitness and in professional sports.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    8th July 2020

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    3rd July 2020

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    1st July 2020

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    17th June 2020

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role

    Oxford BioDynamics

    New questions about Covid-19

    3rd June 2020

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    29th May 2020

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    21st May 2020

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    18th May 2020

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities

    Oxford BioDynamics

    ALS Awareness

    11th May 2020

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in

    Oxford BioDynamics

    ALS Awareness Month This May

    6th May 2020

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated

    Oxford BioDynamics

    Microarray Facility

    29th April 2020

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    22nd April 2020

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.